Response to letter – Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists

Lucie-Marie Scailteux

To cite this version:

Lucie-Marie Scailteux. Response to letter – Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists. European Journal of Cancer, 2017, 87, pp.204. 10.1016/j.ejca.2017.06.042 . hal-01661110

HAL Id: hal-01661110
https://univ-rennes.hal.science/hal-01661110
Submitted on 11 Dec 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
June 16th, 2017

Response to letter to Re: Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists.

To The Editor:

We thank Professor Albertsen for his interest to our study.

We do acknowledge that pre-existing cardiovascular events were assessed on a look-back period of 6 months before starting ADT and we observed few events. As regards history of cardiovascular disease, difference in events definition and timing did not allow any fair comparison between our population-based study and the trials meta-analysed by Albertsen et al. [1] However, as regards cardiovascular risk factors (diabetes mellitus, hypertension, lipid-lowering drug use), results were more consistent.

His meta-analysis raised the hypothesis that GnRH antagonists may lower cardiovascular events or death from any cause when compared with agonists predominantly in men with pre-existing cardiovascular disease (around on third of the population) but a significant result was also found in the whole population. In that latter instance, our results were not in line. Notwithstanding a different composite outcome (more focused), we observed a non-significant result with a large confidence interval, reflecting a lack of power (HR = 1.2; 95%CI, 0.7 to 2.1). However, under the assumption of an unbiased analysis, true hazard ratio is almost surely not below 0.7 and could even reach 2.1. Whatever the interpretation we may choose, this is not in line with the hypothesis of a clinical meaningful protective effect of GnRH antagonists.

Sincerely,

Lucie-Marie SCAILTEUX, PharmD, PhD
Pharmacovigilance, Pharmacoepidemiology and Drug Information Center, Rennes Hospital University
UPRES, EA 7449, REPERES “Research in Pharmacoepidemiology and Access to Care”, Rennes France